Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNE2 | O96020 | 1/20 | 0.40 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.40 |
| ▸ | CDK2 | P24941 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 6/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.36 |
| ▸ | DOT1L | Q8TEK3 | 2/20 | 0.36 |
| ▸ | STK17B | O94768 | 1/20 | 0.36 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL432254 | 0.94 | CCNE2 (0.40) | CCNE2CCNE1CDK2BRD4MAPT | |
| SCHEMBL10077167 | 0.92 | CCNE2 (0.39) | CCNE2CCNE1CDK2BRD4MAPT | |
| SCHEMBL430210 | 0.92 | CCNE2 (0.38) | CCNE2CCNE1CDK2MAPTMCL1 | |
| SCHEMBL434638 | 0.90 | TLR7 (0.36) | CCNE2CCNE1CDK2MAPTMCL1 | |
| SCHEMBL431141 | 0.86 | CCNE2 (0.36) | CCNE2CCNE1CDK2BRD4MCL1 | |
| SCHEMBL459081 | 0.86 | MAPT (0.37) | CCNE2CCNE1CDK2BRD4MAPT | |
| SCHEMBL2684979 | 0.86 | MGMT (0.40) | CCNE2CCNE1CDK2MCL1HDAC1 | |
| SCHEMBL13037056 | 0.85 | CCNE2 (0.37) | CCNE2CCNE1CDK2MAPTMCL1 | |
| SCHEMBL13074311 | 0.84 | TLR7 (0.37) | CCNE2CCNE1CDK2MAPTMCL1 | |
| SCHEMBL10077229 | 0.84 | TLR7 (0.37) | CCNE2CCNE1CDK2MAPTMCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130231480-A1 | SEQUENCE SPECIFIC DOUBLE-STRANDED DNA/RNA BINDING COMPOUNDS AND USES THEREOF | GENEARREST LTD (IL) | 2013-09-05 | — | — | US | disclosed |
| US-20130231480-A1 | SEQUENCE SPECIFIC DOUBLE-STRANDED DNA/RNA BINDING COMPOUNDS AND USES THEREOF | GENEARREST LTD (IL) | 2013-09-05 | — | — | US | disclosed |
| US-20130231480-A1 | SEQUENCE SPECIFIC DOUBLE-STRANDED DNA/RNA BINDING COMPOUNDS AND USES THEREOF | GENEARREST LTD (IL) | 2013-09-05 | — | — | US | disclosed |
| EP-2596102-A2 | SEQUENCE SPECIFIC DOUBLE-STRANDED DNA/RNA BINDING COMPOUNDS AND USES THEREOF | GeneArrest Ltd (IL) | 2013-05-29 | — | — | EP | disclosed |
| WO-2012011114-A2 | SEQUENCE SPECIFIC DOUBLE-STRANDED DNA/RNA BINDING COMPOUNDS AND USES THEREOF | GENEARREST LTD (IL) | 2012-01-26 | — | — | WO | disclosed |
| WO-2012011114-A2 | SEQUENCE SPECIFIC DOUBLE-STRANDED DNA/RNA BINDING COMPOUNDS AND USES THEREOF | GENEARREST LTD (IL) | 2012-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130231480-A1 | SEQUENCE SPECIFIC DOUBLE-STRANDED DNA/RNA BINDING COMPOUNDS AND USES THEREOF | POLM, POLRMT, DDB1 | CCNE2 3214/4885CCNE1 3336/4885CDK2 3802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.